Piramal R&D Spinoff Gets Name, Seeks Foreign Partner
This article was originally published in PharmAsia News
Piramal Healthcare's recently spun-off research and development arm has been named Piramal Life Sciences as it seeks a foreign partner. The new partner, which would have a 10 percent equity in the new company, is expected to be a multinational drug maker with a strong emphasis on drug discovery. The R&D firm has 14 compounds in its research pipeline, four of them undergoing clinical trials, and it already has discovery and development agreements with Lilly, Merck and other major drug research companies. (Click here for more
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.